Bristol's BARACLUDE Tablet for Chronic Hepatitis B Virus Infection Granted Priority Review by Government.Tokyo, Japan, Nov 11, 2005 - (JCNN JCNN Japan Corporate News Network ) - Bristol Pharmaceutical K.K. announced on November 10 that the Ministry of Health, Labor and Welfare has granted the company with a priority review status for BARACLUDE Tablet, an agent for treating chronic hepatitis Chronic hepatitis Long lasting inflammation of the liver due to viruses or other causes. Mentioned in: Tube Compression of the Esophagus and Stomach chronic hepatitis B virus (HBV HBV hepatitis B virus. HBV abbr. hepatitis B virus ) infection, as of November 8. Discovered by Bristol-Myers Squibb, BARACLUDE (entecavil) is an oral nucleoside analogue that selectivity inhibits HBV polymerase. In Japan, it is estimated that more than 10 million people develop chronic HBV infection and about 35,000 people die from liver cancer triggered by HBV infection every year. Bristol Pharmaceutical has filed applications for BARACLUDE, which was initially approved in the US in March 2005, on August 31. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion